Pfizer Inc. $PFE Stake Increased by Intrua Financial LLC

Intrua Financial LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 17.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 78,392 shares of the biopharmaceutical company’s stock after acquiring an additional 11,643 shares during the quarter. Intrua Financial LLC’s holdings in Pfizer were worth $1,986,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Gould Capital LLC grew its stake in Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. acquired a new stake in shares of Pfizer in the first quarter worth $27,000. Bayforest Capital Ltd acquired a new position in Pfizer during the 1st quarter worth $28,000. North Capital Inc. bought a new position in Pfizer in the 1st quarter worth approximately $28,000. Finally, Bernard Wealth Management Corp. bought a new position in Pfizer during the fourth quarter worth $30,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Shares of PFE opened at $24.59 on Thursday. The stock has a market capitalization of $139.79 billion, a price-to-earnings ratio of 13.08, a PEG ratio of 0.88 and a beta of 0.55. The firm has a fifty day simple moving average of $24.83 and a 200 day simple moving average of $24.33. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer’s revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. The ex-dividend date of this dividend was Friday, July 25th. Pfizer’s dividend payout ratio is presently 91.49%.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Citigroup upped their price target on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. HSBC decreased their price objective on shares of Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a research note on Monday, May 19th. Jefferies Financial Group lifted their price target on Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a report on Wednesday, May 21st. Berenberg Bank reduced their price objective on Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a report on Thursday, May 29th. Finally, Bank of America raised their target price on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average target price of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.